About this archived opportunity

The Resuscitation and Prevention of Ischemia-induced Dysfunction (RAPIID) program seeks to deliver a transformative, end-to-end resuscitation system that redefines far-forward trauma care. RAPIID aims for this system to be fieldable, usable, and scalable, providing a capability equivalent or superior to stored whole blood in early resuscitation while removing dependence on cold chain and donor logistics. RAPIID seeks to do this by developing a blood analog system (BAS) comprising sequentially administered blood analog components, integrated with ruggedized delivery formats, point-of-care diagnostics, and clinical practice guidelines (CPGs). To maximize post-program viability of developed products, RAPIID will develop and execute effective regulatory and commercialization strategies and accelerate advanced development through technology readiness level (TRL) 7 (Scale-up and Phase II Clinical Trials)1 for blood analog components and TRL 8 (Clinical Studies)2 for devices and diagnostics. This solicitation is to request proposals addressing ONLY Phase 1 of Task Area (TA)-1 and/or TA-2.

Related opportunities

• RAPIID - TA3Defense Advanced Research Projects Agency (DARPA)·Closes in 4 days
• Rapid Assured Access (R2A)DEPT OF DEFENSE·Closes in 2 days
• Rapid Assured Access (R2A)DEPT OF DEFENSE.DEFENSE MICROELECTRONICS ACTIVITY (DMEA).DEFENSE MICROELECTRONICS ACTIVITY·Closes in 2 days
• Rapid Assured Access (R2A)DEPT OF DEFENSE·Closes in 2 days
• Training and Readiness Accelerator (TReX II) Other Transaction Agreement (OTA) Request for Solutions (RFS): TReXII-26-08 RED-26-08-001: Training Risk Assurance, Compliance, and Evaluation (TRACE) System Prototype ProjectDEPT OF DEFENSE
• RFP - 2-PAM Autoinjectors for Project Bioshield (PBS)HEALTH AND HUMAN SERVICES, DEPARTMENT OF·Closes in 5 days